Roche: Tecentriq helps lung cancer patients live longer
(CercleFinance.com) - A Tecentriq-based combination helped people with small cell lung cancer live longer compared with chemotherapy, Roche said on Tuesday.
The Swiss company today announced results from a Phase III study which showed that Tecentriq and chemotherapy helped people with extensive-stage small cell lung cancer - a particularly difficult-to-treat form of lung cancer - live "significantly longer" compared with chemotherapy alone, with an overall survival of 12.3 months versus 10.3 months.
The combination also significantly reduced the risk of disease worsening or death compared with chemotherapy alone, with progression-free survival of 5.2 months versus 4.3 months.
The Phase III study evaluating the efficacy and safety of Tecentriq enrolled 403 people who were randomised equally.
The Roche shares, listed on SIX Swiss Exchange, are currently up 1.3%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Swiss company today announced results from a Phase III study which showed that Tecentriq and chemotherapy helped people with extensive-stage small cell lung cancer - a particularly difficult-to-treat form of lung cancer - live "significantly longer" compared with chemotherapy alone, with an overall survival of 12.3 months versus 10.3 months.
The combination also significantly reduced the risk of disease worsening or death compared with chemotherapy alone, with progression-free survival of 5.2 months versus 4.3 months.
The Phase III study evaluating the efficacy and safety of Tecentriq enrolled 403 people who were randomised equally.
The Roche shares, listed on SIX Swiss Exchange, are currently up 1.3%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.